A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)

Trial Profile

A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Biogen
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 25 Oct 2019 to 31 Oct 2018.
    • 10 Apr 2018 Planned primary completion date changed from 27 Nov 2018 to 31 Oct 2018.
    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top